[1] |
XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin.
Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
|
[2] |
XIAO Yue, LI Tangfei, XUE Qianfu.
Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
|
[3] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[4] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
[5] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[6] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[7] |
HUANG Kaige, XU Qinhua, WANG Wei.
Interaction effect and predictive efficacy of blood glucose and blood calcium on the prognosis of patients with acute severe pancreatitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1227-1234.
|
[8] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[9] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[10] |
DING Hao, GAO Zhenhua, ZHENG Yun.
Research progress of microRNA in diagnosis and treatment of prostate cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
|
[11] |
ZHOU Guangchen, LIU Yixi, ZHENG Yun.
Colorectal cancer and microRNA: research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
|
[12] |
YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong.
Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
|
[13] |
LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao.
Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
|
[14] |
BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong.
Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
|
[15] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|